AIAxios1h ago
Pathos AI, which uses AI
Pathos AI, which uses AI to develop oncology drugs, raised a $237M Series E at a $3B post-money valuation, up from $1.6B after its $365M Series D in May 2025
TL;DRPathos AI raised $237M for AI-driven cancer drug development at $3B valuation.
Why it matters: Demonstrates investor confidence in AI for drug discovery, potentially accelerating personalized cancer treatments.
Precision oncology biotech Pathos AI said Friday it raised a $237 million Series E round at a $3 billion post-money valuation.
Read full articleSource: Axios · Opens in new tab